盆炎丸治疗女性生殖道解脲支原体感染气虚血瘀证的临床观察

Treatment of Ureaplasma Urealyticum Infection Patients of Qi Deficiency Blood Stasis Syndrome by Pengyan Pill: a Clinical Observation

目的观察盆炎丸治疗女性生殖道解脲支原体感染气虚血瘀证的临床疗效。方法将188例女性生殖道解脲支原体感染气虚血瘀证患者随机分为2组,治疗组98例用盆炎丸,每次10g,每天3次,连续14天为1个疗程;对照组90例口服阿奇霉素,1g,顿服,连续7天为1个疗程。两组均连续治疗3个疗程,观察2组治疗前后临床证候积分,判断其近期临床疗效,并随访其复发情况,判断其远期疗效。结果治疗组综合疗效总有效率为91.4%;对照组总有效率为79.3%,两组比较,差异无统计学意义(P>0.05)。中医证候改善,治疗组明显优于对照组(P<0.01)。两组支原体转阴率比较,差异无统计学意义(P>0.05)。治疗组与对照组复发率分别为12.82%、54.76%,差异有统计学意义(P<0.05)。结论盆炎丸治疗女性生殖道解脲支原体感染气虚血瘀证疗效与阿奇霉素相当,但中医证候改善远期复发率,盆炎丸有明显优势。

Objective To observe the clinical efficacy of Penyan Pill （PP） in treating ureaplasma urealyticum （UU） infection patients of qi deficiency blood stasis syndrome （QDBSS）. Methods Totally 188 UU infection patients of QDBSS were randomly assigned to two groups, the treatment group and the control group. Patients in the treatment group were treated with PP （10 g each time, thrice daily, 14 consecutive days as one therapeatic course）, while those in the control group took azithromycin （10 g each day, 7 consecutive days as one therapeutic course）. They were continually treated for 3 therapeutic courses. The clinical symptom integrals were observed in the two groups before and after treatment. The short-term efficacy was judged. Their recurrence rates were followed-up to assess their long-term efficacies. Results The total effective rate of the comprehensive efficacy in the treatment group was 91.4%, while it was 79.3%in the control group, showing no statistical difference between the two groups （P 0.05）. Better effects were obtained in improving Chinese medical clinical symptoms in the treatment group （P 0.01）. There was no statistical difference in the negative conversion rate between the two groups after treatment （P 0.05）. There was statistical difference in the recurrence rate between the two groups （12.82% vs 54.76%,P 0.05）. Conclusions PP showed equivalent effects in treating UU infection patients of QDBSS to those of azithromycin. But PP showed obvious advantages over azithromycin in improving Chinese medical syndromes.